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Position Statement, Association of American Physicians
The imperative to invest in science has never been greater
In order to sustain and improve the health 
of Americans, to ensure our ability to over-
come new health challenges, and to realize 
the economic benefits of a vigorous scien-
tific economy, we encourage our govern-
ment to implement three actions. First, 
establish predictable, managed growth 
in the US scientific enterprise by estab-
lishing a sustainable and predictable real 
annual increase in science funding. This 
will require additional investments in 
the proven NIH-university partnership 
to maintain our world-leading position 
in biomedical science. Second, preserve 
the current cadre of well-trained junior 
scientists, including physician-scientists, 
and maintain a pipeline of young scien-
tists motivated to innovate and improve 
health. Third, analyze changing health 
needs and priorities for health science–
related investments in order to address 
ongoing shifts in population demo-
graphics and diseases, opportunities for 
improved prevention or treatment, and 
the availability of new scientific tools and 
disciplines.
It is in the nation’s best interests — for 
good health, for a robust economy, and 
for scientific leadership — to advocate for 
strong federal support of biomedical sci-
ence in America’s great research universi-
ties. Translation of this science yields enor-
mous benefits to our nation’s health and to 
the economy.
Over the last 60-plus years, since the cre-
ation of the NIH and other federal agen-
cies that fund science at research univer-
sities and intramurally, the US has led the 
world by investing in the scientists and the 
research that has profoundly improved 
our health. The return on this investment 
has been realized in three ways. First, 
life expectancy of Americans has almost 
doubled over the past century, from 47 
years to over 80. Scientific advances and 
translation into impact — through public 
health and medicine — has contributed sig-
nificantly to this remarkable statistic. Sec-
ond, new diagnostic tests, medical treat-
ments, minimally invasive surgeries, and 
other approaches to improve population 
health have enhanced disease prevention, 
uncovered cures for many diseases, and 
improved health and quality of life. Third, 
the US has led the world scientifically, cata-
lyzing the biotechnology revolution as well 
as the health revolution.
These benefits have been translated 
into an economic engine that has cre-
ated jobs, innovative businesses, and a 
healthier workforce. This momentum has 
also attracted young scientists interested 
in devising new interventions to improve 
health through their own research and 
intellectual enterprise.
Scientific, health, and medical advances 
have occurred because of a dynamic part-
nership between federal agencies and 
America’s great research universities, joint-
ly supporting the world’s leading health 
scientists and their innovative research. 
Neither sector could have achieved these 
benefits alone. Because universities are 
committed to the advancement of knowl-
edge and to free and open access to new 
ideas, the vibrancy of this partnership 
has been the foundation for peerless sci-
entific leadership. The critical mass of 
expertise in our universities, and their 
linkage to patients’ lives and public health 
improvement, has connected basic sci-
ence — from the study of cells to society — 
to improved medical care and improved 
population health.
The American public is justifiably 
proud that our physicians can now deliver 
important lifesaving treatments. Vaccines 
prevent dozens of diseases that ravaged 
previous generations. Heart disease has 
plummeted because of preventive strate-
gies, including lowering cholesterol lev-
els and effective interventions such as 
angioplasty (1). Lifesaving treatments are 
available for infectious diseases, includ-
ing daunting viruses such as HIV. All 
of these have been discovered though 
NIH-funded science in universities, with 
critical leadership provided by physician-
scientists trained and sustained by the 
university model. Patients with arthritis, 
diabetes, heart failure, mental disorders, 
and myriad other chronic diseases now 
have treatment options never imagined a 
few decades ago — treatments that could 
not have emerged from the private sec-
tor alone. Studies of the genetic causes of 
cancer are yielding new treatments that 
are targeted specifically to the cause of the 
tumor. We now transplant kidneys, livers, 
hearts, and lungs with high success rates. 
Each of these advances, and many others, 
can be traced from research advances at 
universities, to new standards of medical 
care and disease prevention, to popula-
tion-based ways to protect all of our health, 
and finally to a robust private sector. Our 
breadth of scientific capabilities — from 
bench to bedside to neighborhoods — is 
unparalleled and is essential to ongoing 
good health and economic prosperity.
Many unsolved and emerging health 
needs remain, however, demanding new 
solutions. Despite advances, we are not 
keeping up. Of deep concern is that US 
health status has declined in recent years 
to the lowest among peer nations (2). Just 
as we face many economic challenges, we 
are confronted by changing health needs, 
yet at the same time, we have science on 
the verge of breakthroughs. Investing in 
the science of the future will matter deep-
ly. It is clear that now is the time to build 
on our immense capabilities, and not let 
them lapse. Furthermore, the complex-
ity of our health needs demand building 
on the new capabilities with high likeli-
hood of health impact, such as specific 
cancer and immunologic breakthroughs, 
while discovering effective prevention for 
emerging conditions, such as obesity and 
Alzheimer’s, that will preserve Americans’ 
health into the oldest ages. The organiza-
tion of science into broad, interdisciplin-
ary collaborative enterprises can catalyze 
breakthroughs and ensure competitive-
ness. The model of success for the US that 
has worked so well as a basis for address-
ing changing opportunities has been 
our commitment to the NIH-university- 
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belts and investing in their long-term 
future. The federal government needs 
to do the same regarding our invest-
ment in science for our nation’s health. 
The alternative is to lose our eco -
nomic engine, our global standing of 
scientific leadership, and our health.
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To preserve our dominant leadership in 
science, we need to make sure that the US 
sustains the pipeline of young physician-
scientists and ensures the strength of 
the research universities that make the 
greatest and most impactful science pos-
sible. We cannot risk losing our research 
infrastructure and an entire generation of 
young scientists by diminished support 
for research. Other countries have rec-
ognized this need. China has identified 
biotechnology as one of seven key strate-
gic initiatives and plans to fund biomedi-
cal research at twice US levels within five 
years (3, 4). Even countries with smaller 
economies, including Korea, Singapore, 
and Taiwan, are outpacing the US’s invest-
ment in life sciences, providing more than 
three times the funding (proportionate to 
GDP) than the US (3, 4).
Strong businesses respond to finan-
cial downturns by both tightening their 
